H.C. Wainwright Starts Generate Biomedicines (GENB) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500, Nasdaq set for lower open as AI stocks slide on debt concerns
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent oil slips as US weighs easing sanctions on Russia's 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts GENB Hot Sheet
Price: $12.68 +1.28%
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 9 | New: 31
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 9 | New: 31
Join SI Premium – FREE
H.C. Wainwright initiates coverage on Generate Biomedicines (NASDAQ: GENB) with a Buy rating and a price target of $16.00.
For an analyst ratings summary and ratings history on Generate Biomedicines click here. For more ratings news on Generate Biomedicines click here.
Shares of Generate Biomedicines closed at $11.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Starts Infleqtion, Inc (INFQ) at Equalweight
- Performance Food Group (PFGC) PT Lowered to $110 at TD Cowen
- Stifel Reiterates Buy Rating on Rocket Lab USA (RKLB) on Long-Term Opportunity
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, H.C. Wainwright, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
